[HTML][HTML] Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in …
A Tanaka, S Uegaki, H Kurihara, K Aida… - World Journal of …, 2007 - ncbi.nlm.nih.gov
A Tanaka, S Uegaki, H Kurihara, K Aida, M Mikami, I Nagashima, J Shiga, H Takikawa
World Journal of Gastroenterology: WJG, 2007•ncbi.nlm.nih.govAIM: To elucidate risk factors contributing to the development of hepatocellular carcinoma
(HCC) among patients with sustained viral response (SVR) after interferon (IFN) treatment
and to examine whether HCV-RNA still remained in the liver of SVR patients who developed
HCC. METHODS: Two-hundred and sixty-six patients, who achieved SVR, were enrolled in
this study. We retrospectively reviewed clinical, viral and histological features of the patients,
and examined whether the development of HCC depends on several clinical variables using …
(HCC) among patients with sustained viral response (SVR) after interferon (IFN) treatment
and to examine whether HCV-RNA still remained in the liver of SVR patients who developed
HCC. METHODS: Two-hundred and sixty-six patients, who achieved SVR, were enrolled in
this study. We retrospectively reviewed clinical, viral and histological features of the patients,
and examined whether the development of HCC depends on several clinical variables using …
Abstract
AIM: To elucidate risk factors contributing to the development of hepatocellular carcinoma (HCC) among patients with sustained viral response (SVR) after interferon (IFN) treatment and to examine whether HCV-RNA still remained in the liver of SVR patients who developed HCC.
METHODS: Two-hundred and sixty-six patients, who achieved SVR, were enrolled in this study. We retrospectively reviewed clinical, viral and histological features of the patients, and examined whether the development of HCC depends on several clinical variables using Kaplan-Meier Method. RT-PCR was used to seek HCV-RNA in 3 out of 7 patients in whom liver tissue was available for molecular analysis.
RESULTS: Among the enrolled 266 patients with SVR, HCC developed in 7 patients (7/266; 2.6%). We failed to detect HCV-RNA both in cancer and non-cancerous liver tissue in all three patients. The cumulative incidence for HCC was significantly different depending on hepatic fibrosis (F3-4)(P= 0.0028), hepatic steatosis (Grade 2-3)(P= 0.0002) and age (≥ 55)(P= 0.021) at the pre-interferon treatment.
CONCLUSION: The current study demonstrated that age, hepatic fibrosis, and hepatic steatosis at pre-interferon treatment might be risk factors for developing HCC after SVR.
ncbi.nlm.nih.gov